We would like to acknowledge the support that the Kemri Wellcome Programme, Kilifi, Kenya gave to this clinical trial in terms of support and guidance. Specifically, Esther Kivaya and Moses Ngari whose help with this study was greatly appreciated. The authors also thank Laura Elson (supported by the Bill & Melinda Gates Foundation) for editing support.

Dedication
We would like to dedicate this paper to the memory of Henok Negussie Seifu, who was the Trial Coordinator on the GoLBeT trial and so we would like to remember him and acknowledge his work though this paper. He is greatly missed by his colleagues.